Skip to main content
SpringerLink
Log in

Eradication of cervical cancer: the beginning of the end

  • News and Views
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19

    Article  CAS  PubMed  Google Scholar 

  2. Ali H, Guy RJ, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Donovan B (2013) Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 13:140

    Article  PubMed Central  PubMed  Google Scholar 

  3. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM (2013) Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 11:227

    Article  PubMed  Google Scholar 

  4. Luxembourg A (2013) An overview of the 9-valent HPV L1 virus-like particle vaccine clinical development program. In: EUROGIN 2013 congress proceedings, Florence, Italy, p 101

  5. Joura EA, team. Obot V-s (2013) Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. In: EUROGIN 2013 congress proceedings, Florence, Italy, p 102

  6. Van Damme P, Vesikari T, Brodszki N, Diez-Domingo J, Icardi G, Petersen L-K, Tran C, Thomas S, Baudin M (2013) Efficacy and safety of a novel 9-valent HPV L1 virus-like particle vaccine in girls 9–15 years of age compared to the quadrivalent vaccine. In: EUROGIN 2013 congress proceedings, Florence, Italy, p 103

  7. Giulian AR, Obot V-a-st (2013) Efficacy and tolerability of a novel 9-valent HPV L1 virus-like particle vaccine in boys/girls age 9–15 and women age 16–26. In: EUROGIN 2013 congress proceedings, Florence, Italy, p 103

  8. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ (2013) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. doi:10.1016/S0140-6736(13)62218-7

Download references

Conflict of interest

P. Hillemanns received lecture fees from SPMSD and research grant from GSK.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Medical University Hannover, Carl-Neubergstr. 1, 30625, Hannover, Germany

    Peter Hillemanns

Authors
  1. Peter Hillemanns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Hillemanns.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hillemanns, P. Eradication of cervical cancer: the beginning of the end. Arch Gynecol Obstet 289, 477–478 (2014). https://doi.org/10.1007/s00404-013-3127-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-3127-y

Keywords

Search

Navigation